


## Mc-VC-PAB-SN38

<b>Cat. No.:</b>	HY-131057
<b>CAS No.:</b>	1801838-28-7
<b>Molecular Formula:</b>	C <sub>51</sub> H <sub>58</sub> N <sub>8</sub> O <sub>13</sub>
<b>Molecular Weight:</b>	991.05
<b>Target:</b>	Drug-Linker Conjugates for ADC
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related
<b>Storage:</b>	-20°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 28.57 mg/mL (28.83 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	1.0090 mL	5.0452 mL	10.0903 mL
		5 mM	0.2018 mL	1.0090 mL	2.0181 mL
10 mM		0.1009 mL	0.5045 mL	1.0090 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.86 mg/mL (2.89 mM); Suspended solution; Need ultrasonic				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Mc-VC-PAB-SN38 consists a cleavable ADC linker (Mc-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). Mc-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs) <sup>[1]</sup> .
<b>In Vitro</b>	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA